EXICURE, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
EXICURE, INC. (XCUR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.00K, a 83.33% decline year-over-year.
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-09-30 was $5.00K, a 90.00% decline year-over-year.
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-06-30 was $6.00K, a 99.38% decline year-over-year.
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $5.00K, a 98.38% decline year-over-year.
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.00K, a 90.91% decline from fiscal 2024.
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $22.00K, a 98.37% decline from fiscal 2023.
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.35M, a 1.53% decline from fiscal 2022.
- EXICURE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.37M, a 53.42% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.00K 10-K · filed 2026-03-25 | |||
| 2025-06-30 | $1.00K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $22.00K 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $5.00K 10-Q · filed 2025-11-07 | $11.00K derived: sum of 2 quarters · filed 2025-11-07 | $16.00K derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $6.00K 10-Q · filed 2025-11-07 | $11.00K derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $5.00K 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $1.35M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $50.00K 10-Q · filed 2024-11-14 | $1.02M derived: sum of 2 quarters · filed 2024-11-14 | $1.33M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $969.00K 10-Q · filed 2024-11-14 | $1.28M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $308.00K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $1.37M 10-K · filed 2024-06-06 | |||
| 2022-09-30 | $292.00K 10-Q · filed 2024-05-16 | $799.00K derived: sum of 2 quarters · filed 2024-06-06 | $1.14M derived: sum of 3 quarters · filed 2024-06-06 | |
| 2022-06-30 | $507.00K 10-Q/A · filed 2024-06-06 | $849.00K derived: sum of 2 quarters · filed 2024-06-06 | ||
| 2022-03-31 | $342.00K 10-Q/A · filed 2024-06-06 | |||
| 2021-12-31 | $2.94M 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $889.00K 10-Q · filed 2022-11-14 | $1.65M derived: sum of 2 quarters · filed 2022-11-14 | $2.17M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $764.00K 10-Q · filed 2022-11-14 | $1.28M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $517.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $2.18M 10-K · filed 2022-03-25 | |||
| 2020-09-30 | $617.00K 10-Q · filed 2021-11-19 | $1.16M derived: sum of 2 quarters · filed 2021-11-19 | $1.60M derived: sum of 3 quarters · filed 2021-11-19 | |
| 2020-06-30 | $544.00K 10-Q · filed 2021-11-19 | $985.00K derived: sum of 2 quarters · filed 2021-11-19 | ||
| 2020-03-31 | $441.00K 10-Q · filed 2021-11-19 | |||
| 2019-12-31 | $1.84M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $511.00K 10-Q · filed 2020-11-12 | $950.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.44M derived: sum of 3 quarters · filed 2020-11-12 | $1.95M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $439.00K 10-Q · filed 2020-11-12 | $928.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.44M derived: sum of 3 quarters · filed 2020-11-12 | $1.95M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-03-31 | $489.00K 10-Q · filed 2020-11-12 | $998.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.51M derived: sum of 3 quarters · filed 2020-11-12 | $1.93M derived: sum of 4 quarters · filed 2020-11-12 |
| 2018-12-31 | $509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $1.02M derived: sum of 2 quarters · filed 2020-03-10 | $1.44M derived: sum of 3 quarters · filed 2020-03-10 | $1.81M 10-K · filed 2020-03-10 |
| 2018-09-30 | $516.00K 10-Q · filed 2019-11-07 | $935.00K derived: sum of 2 quarters · filed 2019-11-07 | $1.30M 10-Q · filed 2018-11-06 | $1.66M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $419.00K 10-Q · filed 2019-11-07 | $784.00K 10-Q · filed 2018-08-06 | $1.14M derived: sum of 3 quarters · filed 2019-11-07 | |
| 2018-03-31 | $365.00K 10-Q · filed 2019-11-07 | $723.00K derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2017-12-31 | $358.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-09-23 | $1.46M 10-K/A · filed 2019-09-23 | ||
| 2017-09-30 | $1.10M 10-Q · filed 2017-11-14 | |||
| 2016-12-31 | $682.00K 10-K · filed 2018-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |